WEKO3
アイテム
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
https://kagawa-u.repo.nii.ac.jp/records/335
https://kagawa-u.repo.nii.ac.jp/records/3359f046506-56d1-4a12-820d-ed4003629d29
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
|
![]() |
|
|
![]() |
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
公開日 | 2018-10-11 | |||||||||||||
タイトル | ||||||||||||||
言語 | en | |||||||||||||
タイトル | Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) | |||||||||||||
言語 | ||||||||||||||
言語 | eng | |||||||||||||
資源タイプ | ||||||||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||||||||
資源タイプ | doctoral thesis | |||||||||||||
アクセス権 | ||||||||||||||
アクセス権 | open access | |||||||||||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||
著者 |
山﨑, 健太郎
× 山﨑, 健太郎
|
|||||||||||||
抄録 | ||||||||||||||
内容記述タイプ | Abstract | |||||||||||||
内容記述 | Background FOLFIRI and FOLFOX have shown equivalent efficacy for metastatic colorectal cancer (mCRC), but their comparative effectiveness is unknown when combined with bevacizumab. |
|||||||||||||
言語 | en | |||||||||||||
抄録 | ||||||||||||||
内容記述タイプ | Abstract | |||||||||||||
内容記述 | Patients and methods WJOG4407G was a randomized, open-label, phase III trial conducted in Japan. Patients with previously untreated mCRC were randomized 1:1 to receive either FOLFIRI plus bevacizumab (FOLFIRI + Bev) or mFOLFOX6 plus bevacizumab (mFOLFOX6 + Bev), stratified by institution, adjuvant chemotherapy, and liver-limited disease. The primary end point was non-inferiority of FOLFIRI + Bev to mFOLFOX6 + Bev in progression-free survival (PFS), with an expected hazard ratio (HR) of 0.9 and non-inferiority margin of 1.25 (power 0.85, one-sided α-error 0.025). The secondary end points were response rate (RR), overall survival (OS), safety, and quality of life (QoL) during 18 months. This trial is registered to the University Hospital Medical Information Network, number UMIN000001396. |
|||||||||||||
言語 | en | |||||||||||||
抄録 | ||||||||||||||
内容記述タイプ | Abstract | |||||||||||||
内容記述 | Results Among 402 patients enrolled from September 2008 to January 2012, 395 patients were eligible for efficacy analysis. The median PFS for FOLFIRI + Bev (n = 197) and mFOLFOX6 + Bev (n = 198) were 12.1 and 10.7 months, respectively [HR, 0.905; 95% confidence interval (CI) 0.723–1.133; P = 0.003 for non-inferiority]. The median OS for FOLFIRI + Bev and mFOLFOX6 + Bev were 31.4 and 30.1 months, respectively (HR, 0.990; 95% CI 0.785–1.249). The best overall RRs were 64% for FOLFIRI + Bev and 62% for mFOLFOX6 + Bev. The common grade 3 or higher adverse events were leukopenia (11% in FOLFIRI + Bev/5% in mFOLFOX6 + Bev), neutropenia (46%/35%), diarrhea (9%/5%), febrile neutropenia (5%/2%), peripheral neuropathy (0%/22%), and venous thromboembolism (6%/2%). The QoL assessed by FACT-C (TOI-PFC) and FACT/GOG-Ntx was favorable for FOLFIRI + Bev during 18 months. |
|||||||||||||
言語 | en | |||||||||||||
抄録 | ||||||||||||||
内容記述タイプ | Abstract | |||||||||||||
内容記述 | Conclusion FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus bevacizumab, as the first-line systemic treatment for mCRC. |
|||||||||||||
言語 | en | |||||||||||||
学位名 | ||||||||||||||
言語 | ja | |||||||||||||
学位名 | 博士(医学) | |||||||||||||
学位授与機関 | ||||||||||||||
識別子Scheme | kakenhi | |||||||||||||
識別子 | 16201 | |||||||||||||
言語 | ja | |||||||||||||
機関名 | 香川大学 | |||||||||||||
言語 | en | |||||||||||||
機関名 | Kagawa University | |||||||||||||
学位授与年月日 | ||||||||||||||
学位授与年月日 | 2018-09-27 | |||||||||||||
学位授与番号 | ||||||||||||||
学位授与番号 | 乙第286号 | |||||||||||||
権利 | ||||||||||||||
言語 | en | |||||||||||||
権利情報 | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. | |||||||||||||
PubMed番号 | ||||||||||||||
識別子タイプ | PMID | |||||||||||||
関連識別子 | 27177863 | |||||||||||||
関連サイト | ||||||||||||||
関連タイプ | isVersionOf | |||||||||||||
識別子タイプ | DOI | |||||||||||||
関連識別子 | https://doi.org/10.1093/annonc/mdw206 | |||||||||||||
他の資源との関係 | ||||||||||||||
関連名称 | Clinical trials number: UMIN000001396 | |||||||||||||
著者版フラグ | ||||||||||||||
出版タイプ | NA | |||||||||||||
出版タイプResource | http://purl.org/coar/version/c_be7fb7dd8ff6fe43 | |||||||||||||
キーワード | ||||||||||||||
言語 | en | |||||||||||||
主題Scheme | Other | |||||||||||||
主題 | irinotecan | |||||||||||||
キーワード | ||||||||||||||
言語 | en | |||||||||||||
主題Scheme | Other | |||||||||||||
主題 | oxaliplatin | |||||||||||||
キーワード | ||||||||||||||
言語 | en | |||||||||||||
主題Scheme | Other | |||||||||||||
主題 | bevacizumab | |||||||||||||
キーワード | ||||||||||||||
言語 | en | |||||||||||||
主題Scheme | Other | |||||||||||||
主題 | colorectal cancer | |||||||||||||
キーワード | ||||||||||||||
言語 | en | |||||||||||||
主題Scheme | Other | |||||||||||||
主題 | phase III study | |||||||||||||
KEID | ||||||||||||||
28522 |